Table 5.
Top Canonical Pathways | p-value | Overlap | Ratio |
---|---|---|---|
Super-pathway of Cholesterol Biosynthesis | 7.68E-10 | 39.3% | 11/28 |
Tryptophan Degradation III | 3.74E-09 | 40.0% | 10/25 |
Sirtuin Signaling Pathway | 6.93E-08 | 10.3% | 30/292 |
Cholesterol Biosynthesis I-II | 6.99E-08 | 53.8% | 7/13 |
LPS/IL-1 Mediated Inhibition of RXR Function | 5.58E-07 | 10.8% | 24/222 |
Top Upstream Regulators predicted by IPA | p-value of overlap | # Target genes | |
PPARA | 1.41E-20 | 62 | |
NFE2L2 | 1.09E-14 | 50 | |
HNF4A | 3.61E-12 | 134 | |
PPARGC1A | 4.21E-12 | 34 | |
SREBF2 | 5.77E-12 | 19 | |
Top Molecular and Cellular Functions | p-value | # Genes | |
Lipid Metabolism | 1.23E-03 - 6.04E-16 | 181 | |
Molecular Transport | 1.28E-03 - 6.04E-16 | 190 | |
Small Molecule Biochemistry | 1.28E-03 - 6.04E-16 | 237 | |
Vitamin and Mineral Metabolism | 1.14E-03 - 5.30E-14 | 64 | |
Amino Acid Metabolism | 1.14E-03 - 3.22E-10 | 38 | |
Physiological System Development and Function | p-value | # Genes | |
Digestive System Development and Function | 1.14E-03 - 6.09E-09 | 87 | |
Hepatic System Development and Function | 1.14E-03 - 6.09E-09 | 67 | |
Organ Morphology | 7.07E-04 - 6.09E-09 | 46 | |
Organismal Development | 1.22E-03 - 6.09E-09 | 147 | |
Embryonic Development | 1.22E-03 - 3.24E-08 | 55 | |
Up-regulated genes | FAST48h/REFED48h | Down-regulated genes | FAST48h/REFED48h |
IGFBP2 | 3.31 | THRSPA | −6.47 |
ADSL | 3.21 | ME1 | −4.97 |
CYP3A7 | 2.51 | SCD | −4.55 |
CYP4A22 | 2.39 | LGALS2 | −4.14 |
BHMT | 2.34 | PLIN2 | −3.64 |
AIF1L | 2.31 | FADS2 | −3.86 |
LDHB | 2.16 | CYP51A1 | −3.56 |
ABCG5 | 2.06 | DIO2 | −2.71 |
NDRG1 | 2.04 | ENOVL6 | −2.59 |
AKR1D1 | 1.97 | MSMO1 | −2.58 |
aIngenuity Pathway Analysis (IPA) was used for functional analysis of 750 “Analysis Ready” (AR)-DEGs from the D2FAST48h vs. D4REFED48h contrast. The top 10 up-regulated and down-regulated AR-DEGs are presented along with their respective log2 ratio of treatment conditions, where positive numbers indicate higher expression in the D2FAST48h treatment and negative values indicate higher expression in the D4REFED48h treatment condition